Is there a role for in vivo methylene blue staining in the prediction of bladder tumour recurrence

Objective To assess the role of in vivo staining with intravesical methylene blue in predicting tumour recurrence. Patients and methods Thirty-nine patients (2 7 men and 12 women, age range 43–75 years) newly diagnosed with bladder tumours were prospectively studied and followed for a minimum of 2 years. Potential biopsy sites were identified by staining intravesically with a 1% methylene blue solution and compared with random biopsy sites. Results Biopsy directed by methylene blue staining detected carcinoma in situ more often than random biopsy. Rates of recurrence were similar in both stained and unstained groups. Conclusion methylene blue staining does not add significantly to the management of patients presenting with bladder tumours.